Sandra Beaty - Zoetis Executive Vice President - Corporate Affairs

<div class='circular--portrait' style='background:#2A0CD0;color: white;font-size:3em;padding-top: 25px;;'>ZTS</div>
ZTS -- USA Stock  

Earning Report: February 13, 2020  

  President
Ms. Sandra J. Beaty serves as Executive Vice President Corporationrationrate Affairs of Zoetis Inc. Ms. Beaty joined Pfizer in 1996 and held various positions including Senior Vice President of Public Affairs and Chief of Staff to the former Pfizer Chairman and CEO.
Age: 56  President Since 2012      
973 822-7000  www.zoetis.com

Sandra Beaty Latest Insider Activity

Management Efficiency

The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Paul SilvaVertex Pharmaceuticals Incorpor
2019
Scott JamisonPerrigo Company Plc
2011
Samiran DasDr Reddys Laboratories Ltd
2016
K RaoDr Reddys Laboratories Ltd
2016
Ian SmithVertex Pharmaceuticals Incorpor
2017
Louis YuPerrigo Company Plc
2013
Raghav ChariDr Reddys Laboratories Ltd
2013
Ronald JanishPerrigo Company Plc
2015
Svend AndersenPerrigo Company Plc
2017
Douglas BoothePerrigo Company Plc
2013
James MichaudPerrigo Company Plc
2016
James DillardPerrigo Company Plc
2019
Thomas FarringtonPerrigo Company Plc
2015
Paul WeningerPerrigo Company Plc
2015
Marc CouckePerrigo Company Plc
N/A
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Daniel PlewRegeneron Pharmaceuticals
2016
Jeffrey NeedhamPerrigo Company Plc
2009
J RamachandranDr Reddys Laboratories Ltd
2016
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Michael PariniVertex Pharmaceuticals Incorpor
2017

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Also Currentnly Active

Purchased few shares of
a day ago
Traded for 55.68
Purchased few shares of
a day ago
Traded for 85.37
Purchased one share of
a day ago
Traded for 209.15
See also Your Current Watchlist. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.